Aug. 4 at 10:04 PM
$VKTX idiot shorts have no common sense, taking about long term and BS. you know who?
TSLA was also under
$100 when it was only developing (in phase trials), took over 8 years to produce 1 EV. Also, TSLA was close to bankrupt once. Now, TSLA's
$4,500/share (before 2 splits), dominating EV market, except in China. VKTX is currently the best in both efficacy and side effects, SUPERIOR. LLY 21% in 72 weeks (the #1 in current market) vs VKTX 15% in 13 weeks, have both subQ and oral form. When VKTX comes to the public, which one would people going to like? So, with VKTX, the time is really irrelevant. Because by 2030, the obesity market is
$150 B. Even if VKTX could only take 10%, generating
$15 B annually, that means VKTX is nearly
$90 B m.c. (
$800/share). LLY's
$700 B m.c., NVO's
$200 B m.c. , but only
$4 B m.c. for VKTX.
$35,
$50,
$80, or
$100/share now, after 3 years, it would be like TSLA.
